Report | the CAGR of the global nasal polyp treatment market reaches 5%, drug treatment is dominant, and Mercedes-Benz, Sanofi and Pfizer participate in the competition.

新浪醫藥 · May 17, 2021 18:00

编译丨范东东

日前，透明市场研究（TMR）发布了有关2019年至2027年预测期的鼻息肉治疗市场的最新市场分析报告。根据该报告显示， 2018年全球鼻息肉治疗市场价值约为39亿美元，并且预计从2019年到2027年的年复合增长率（CAGR）将达到5％。

鼻息肉治疗市场概述

因患有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）的老年人口日益增加，发达地区的耳鼻喉科医生外科医生对微创外科手术更加高频的使用，以及鼻息肉治疗渠道日益丰富，TMR预计全球鼻息肉治疗市场份额将得到推动。

北美地区在2018年在全球鼻息肉治疗市场中占据了主要份额，比如美国的鼻窦植入物需求旺盛。从2019年到2027年，亚太地区的鼻息肉治疗市场预计将以6％的高复合年增长率增长，原因是患有炎性呼吸系统疾病的目标患者人数激增，这很可能会推动包括印度和中国等在内的新兴市场鼻息肉治疗手术数量增加。

全球CRSwNP流行带动市场增长

TMR预计从2019年到2027年，诸如CRSwNP、哮喘、鼻息肉和变应性鼻炎等炎症和呼吸系统疾病的流行将增加全球鼻息肉治疗市场。

慢性鼻-鼻窦炎（CRS）是一种鼻炎性疾病，会影响鼻腔和鼻旁窦内部的组织，导致症状持续8周至12周或更长时间。该疾病可伴有或不伴有鼻息肉而发生。CRS被认为是一种严重的鼻部疾病，在60岁及以上的老年人中患病率为 4.7％。此外，该病也是排名第6的影响老年人口的常见慢性病。

因此，慢性呼吸道疾病例如CRSwNP的患病率增加和治疗负担增加，将推动患者对治疗和疗法的市场需求。这可能导致鼻窦外科手术数量的增加，从而有可能在未来几年内加速全球鼻息肉治疗市场的增长。

现有的治疗方法

在治疗方面，全球鼻息肉治疗市场可分为药物疗法和外科手术。药物疗法可分为抗生素、皮质类固醇、白三烯抑制剂等。手术部分可分为息肉切除术和功能性内窥镜鼻窦手术（FESS）。

药物治疗领域在2018年主导了全球鼻息肉治疗市场，预计这一趋势在预测期内将持续下去。

鼻内类固醇喷雾剂、全身和口服皮质类固醇、鼻腔冲洗盐水和抗生素等药物疗疗法被广泛用于治疗鼻息肉CRSwNP患者。此外，对局部和全身性皮质类固醇的需求增加，有望最大程度地减少鼻息肉的大小并防止鼻息肉再次生长，有望促进鼻息肉治疗市场的增长。

医院有望成为手术治疗的增长点

用于鼻息肉的手术治疗包括：息肉切除术和功能性内窥镜鼻窦手术（FESS）在内的手术选择，主要在非卧床住院的手术中心、医院和专科诊所进行。由于在全球范围内被诊断出患有鼻息肉的患者数量正在增加，导致在手术室进行的鼻窦外科手术迅速增加，医院的细分市场预计将在预测期内以高CAGR的速度实现增长。

TMR认为，该部门的增长归因于医院专业护理服务的可用性增加以及医院中合格医疗保健专业人员的涌现。预计在未来几年中，门诊手术中心的市场将快速增长。由于效率更高，患者满意度更高，住院时间最短以及感染率降低，从鼻窦外科手术室到门诊手术中心转移的患者数量增加，可能会促进鼻息肉治疗市场的增长。

北美表现突出，亚太地区是未来的增量机会

就区域而言，全球鼻息肉治疗市场已细分为北美、欧洲、拉丁美洲、亚太地区以及中东和非洲。预计在预测期内，由于鼻息肉的患者人数增加，北美将继续在全球鼻息肉治疗市场中占据领先份额。例如，美国每年报告近200,000例新的鼻息肉病例，这有望提高鼻息肉的治疗率。反过来，这也有望推动患者对药物治疗的需求，并增加美国进行的鼻窦手术的数量。此外，美国鼻息肉治疗的付费和报销方案可能会进一步推动北美鼻息肉治疗市场。

预计未来几年，亚太地区的鼻息肉治疗市场将快速增长。预计中国、印度和韩国在预测时将迎来利润丰厚的鼻息肉市场，因为该地区受鼻息肉CRSwNP影响的患者人数正在增加。根据国家生物技术信息中心（NCBI）的数据，大约8％的中国人口和6.9％的韩国人口受到慢性鼻-鼻窦炎的影响。该疾病可能与鼻息肉一起发生，并可能导致鼻阻塞、面部疼痛和鼻窦发炎，这些难以忍受的症状也可能会推动新兴市场患者对治疗和药物的需求。

鼻息肉主要制药厂商的市场增长策略

在全球鼻息肉治疗市场上运作的主要参与者是默沙东、赛诺菲、辉瑞、葛兰素史克、诺华，以及Intersect ENT和OptiNose US，Inc.，还包括罗氏和再生元。这些公司主要的市场行为，包括从事研发活动以及新产品发布的战略合作和伙伴关系，以扩大产品范围和客户群。

2018年4月，Intersect ENT宣布在美国推出SINUVA鼻窦植入物。SINUVA鼻窦植入物是一种糠酸莫米松类固醇洗脱鼻窦植入物，用于治疗已经进行过鼻窦手术的复发性鼻息肉。

在获得美国FDA批准4个月后，2019年10月赛诺菲与合作伙伴再生元宣布欧盟委员会（EC）已批准Dupixent（dupilumab）做为鼻内皮质内固醇的一种附加疗法，用于治疗系统性皮质类固醇和/或手术治疗不能提供足够疾病控制的伴鼻息肉的慢性鼻-鼻窦炎（CRSwNP）成人患者。

2020年4月，葛兰素史克宣布旗下抗IL-5单克隆抗体Nucala（mepolizumab），在治疗伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者的关键性3期临床试验SYNAPSE中，达到了试验的主要终点和关键性次要终点。

2020年12月，罗氏和诺华合作的Xolair (omalizumab) 预充注射器被批准用于治疗鼻息肉，作为鼻内皮质类固醇（INC）的附加（add-on）疗法，用于治疗采用INC不能充分控制病情的严重慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）成人患者（≥18岁）。

2021年5月，OptiNose公布2021财年第一财季财报，归属于母公司普通股股东净利润为-2605.30万美元，同比增长9.71%；营业收入为1196.00万美元，同比上涨69.36%。OptiNose的主要产品是XHANCE(氟提松)鼻喷剂，利用独有的呼吸式呼出系统，是治疗慢性鼻窦炎和鼻息肉一种有效的抗炎皮质类固醇激素。

参考来源：Nasal Polyps Treatment Market: Pharmacological therapies segment dominated the global market

END

Compiled by Fan Dongdong

A few days ago, transparent Market Research (TMR) released the latest market analysis report on the nasal polyp treatment market for the forecast period from 2019 to 2027. According to the report, the global market for nasal polyps is worth about $3.9 billion in 2018 and is expected to grow at a compound annual growth rate of 5 per cent from 2019 to 2027.

An overview of the market for the treatment of nasal polyps

Due to the increasing elderly population of chronic rhinosinusitis ((CRSwNP)) with nasal polyps, the increased use of minimally invasive surgery by otorhinolaryngologists in developed regions, and the increasing availability of treatment channels for nasal polyps, TMR expects the global market share for nasal polyps treatment to be boosted.

North America accounted for a major share of the global nasal polyp treatment market in 2018, such as strong demand for sinus implants in the United States.The nasal polyp treatment market in the Asia-Pacific region is expected to grow at a high CAGR of 6% from 2019 to 2027.The reason is the increase in the number of target patients with inflammatory respiratory diseases.This is likely to boost the number of surgeries for nasal polyps in emerging markets, including India and China.

Global CRSwNP popularity drives market growth

TMR predicts that the prevalence of inflammatory and respiratory diseases such as CRSwNP, asthma, nasal polyps and allergic rhinitis will increase the global market for nasal polyps treatment from 2019 to 2027.

Chronic rhinosinusitis ((CRS)) is a rhinitis disease that affects tissue in the nasal cavity and paranasal sinuses, causing symptoms to last from 8 to 12 weeks or more. The disease may occur with or without nasal polyps. CRS is considered to be a serious nasal disease, with a prevalence rate of 4.7% in people aged 60 and over. In addition, the disease is also the sixth most common chronic disease affecting the elderly population.

Therefore, the increased prevalence and treatment burden of chronic respiratory diseases such as CRSwNP will boost the market demand for treatment and treatment. This could lead to an increase in the number of sinus surgeries, which could accelerate the growth of the global market for nasal polyps in the next few years.

Existing treatments

In terms of treatment, the global market for nasal polyps can be divided into drug therapy and surgery. Drug therapy can be divided into antibiotics, corticosteroids, leukotriene inhibitors and so on. The operative part can be divided into polypectomy and functional endoscopic sinus surgery ((FESS)).

The field of drug therapy dominated the global nasal polyp treatment market in 2018, and this trend is expected to continue during the forecast period.

Intranasal steroid sprays, systemic and oral corticosteroids, nasal irrigation saline and antibiotics are widely used in the treatment of CRSwNP patients with nasal polyps. In addition, the increased demand for local and systemic corticosteroids is expected to minimize the size of nasal polyps and prevent nasal polyps from growing again, which is expected to promote the growth of the nasal polyp treatment market.

Hospitals are expected to become a growth point for surgical treatment.

Surgical options for nasal polyps include polypectomy and functional endoscopic sinus surgery ((FESS)), mainly in ambulatory surgery centers, hospitals and specialist clinics. Due to the increasing number of patients diagnosed with nasal polyps worldwide, resulting in a rapid increase in sinus surgery performed in operating rooms, the hospital market segment is expected to grow at a high CAGR rate during the forecast period.

TMR attributed the growth in the sector to the increased availability of professional care services in hospitals and the emergence of qualified health care professionals in hospitals. It is expected that the market for outpatient surgery centers will grow rapidly in the next few years. Due to higher efficiency, higher patient satisfaction, shorter hospital stay and lower infection rate, the increase in the number of patients transferred from sinus surgery operating rooms to outpatient surgery centers may contribute to the growth of the nasal polyp treatment market.

North America is outstanding, and the Asia-Pacific region is an incremental opportunity for the future.

Regionally, the global nasal polyp treatment market has been subdivided into North America, Europe, Latin America, the Asia-Pacific region, the Middle East and Africa. It is expected that North America will continue to take the lead in the global nasal polyp treatment market during the forecast period due to the increase in the number of patients with nasal polyps. For example, nearly 200000 new cases of nasal polyps are reported in the United States each year, which is expected to improve the treatment rate of nasal polyps. In turn, it is expected to boost patients' demand for drug treatment and increase the number of sinus surgeries performed in the United States. In addition, payment and reimbursement programs for nasal polyps in the United States may further boost the North American nasal polyp treatment market.

The market for nasal polyps in the Asia-Pacific region is expected to grow rapidly in the next few years. China, India and South Korea are expected to usher in lucrative nasal polyp markets as the number of patients affected by nasal polyps CRSwNP is increasing in the region. According to (NCBI), the national biotechnology information center, about 8 per cent of the Chinese population and 6.9 per cent of the South Korean population are affected by chronic rhinosinusitis. The disease can occur with nasal polyps and can lead to nasal obstruction, facial pain and sinus inflammation, and these unbearable symptoms may also boost demand for treatment and drugs among patients in emerging markets.

Market growth strategy of major pharmaceutical manufacturers of nasal polyps

The main players operating in the global nasal polyp treatment market areMerck, Sanofi,Pfizer、GlaxoSmithKline, Novartis, andIntersect ENT和OptiNoseUS,Inc., also includesRocheAnd regenerative yuan. The main market activities of these companies include strategic cooperation and partnerships in R & D activities and new product launches to expand the product range and customer base.

In April 2018, Intersect ENT announced the launch of SINUVA sinus implants in the United States. The SINUVA sinus implant is a momethasone furoate steroid eluting sinus implant for the treatment of recurrent nasal polyps that have undergone sinus surgery.

Four months after obtaining approval from FDA in the United States, Sanofi and partner Zaiyuan announced in October 2019 that the European Commission (EC) has approved Dupixent (dupilumab) as an additional therapy for intranasal corticosteroids and / or surgery for adult (CRSwNP) patients with chronic rhinosinusitis with nasal polyps that do not provide adequate disease control.

In April 2020, GlaxoSmithKline announced that its anti-IL-5 monoclonal antibody Nucala (mepolizumab), had reached the primary and critical secondary endpoints in the critical Phase 3 clinical trial SYNAPSE in the treatment of chronic sinusitis patients with nasal polyps.

In December 2020, the Roche and Novartis Xolair (omalizumab) pre-filling syringe was approved for the treatment of nasal polyps as an addition to the intranasal corticosteroid (INC) (add-on) therapy for adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (≥ 18 years old) whose condition could not be adequately controlled by INC.

In May 2021, OptiNose announced its financial results for the first quarter of fiscal year 2021. The net profit of common shareholders belonging to the parent company was-26.053 million US dollars, an increase of 9.71% over the same period last year.business incomeIt was US $11.96 million, up 69.36% from the same period last year. OptiNose's main product is XHANCE nasal spray, which uses a unique respiratory exhalation system and is an effective anti-inflammatory corticosteroid for the treatment of chronic sinusitis and nasal polyps.

Reference Source: Nasal Polyps Treatment Market: Pharmacological therapies segment dominated the global market

END

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

报告｜全球鼻息肉治疗市场CAGR达5％，药物治疗占主导，默沙东、赛诺菲、辉瑞等参与竞争

Report | the CAGR of the global nasal polyp treatment market reaches 5%, drug treatment is dominant, and Mercedes-Benz, Sanofi and Pfizer participate in the competition.

Risk Disclaimer

Statement